| Detailed information |
|---|
| CancerLivER ID | 2051 |
| Biomarker | EpCAM |
| Biomarker Name/Symbol (given in Publication) | EpCAM |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarker for hypoxia in HCC and ICC tissues and validated on independent dataset |
| Experimental Condition | HCC v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated for CTCs in patients with HCC. |
| Level of significance | p = 0.595 |
| Source | Blood |
| PMID | 27034142 |
| Type of Biomarker | Diagnostic |
| Pathway | Leukocyte migration, stem cell differentiation, positive regulation of cell proliferation and cell-cell adhesion |
| Cohort | 23 patients with HCC, two with cholangiocarcinoma (CC), one with combined HCC-CC, and three with metastatic carcinomas (two colorectal adenocarcinomas and one nasopharyngeal carcinoma) ; seven cell lines in cluding 6 HCC cell line i.e. HepG2, PLC/PRF5, and Huh-7 etc and two colon cancer cell lines |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02729493,NCT03146637,NCT01974661 |